Retrospective Analysis Comparing the Effectiveness of Epoetin Alfa and Darbepoetin Alfa in Cancer Related and Chronic Kidney Disease Related Anemia Patients
This retrospective analysis compares Epoetin Alfa and Darbepoetin Alfa in the treatment of patients with anaemia with cancer and anaemia with chronic kidney disease. Both erythropoiesis-stimulating agents (ESAs) stimulate erythropoiesis by modelling the natural hormone erythropoietin. Epoetin Alfa and Darbepoetin Alfa have significant structural and pharmacokinetic differences. Epoetin Alfa has a shorter half-life and needs to be administered more frequently, whereas Darbepoetin Alfa has a longer half-life and can be administered less frequently. However, they both increase the risk of thromboembolic events (TEE). This review explores the mechanisms of increased risk of TEE, evaluates clinical data, and discusses strategies to reduce risk. Clinical evidence suggests that Darbepoetin Alfa has a lower incidence of TEE compared to Epoetin Alfa. Individualisation of medication, regular haemoglobin monitoring and thromboprophylaxis in high-risk patients are essential to optimise treatment. The paper highlights the necessity of further research into safer alternatives. In summary, darbepoetin alfa may be a priority for stable patients due to its pharmacokinetic advantages and reduced risk of TEE. This article provides options to healthcare professionals for prescribing the drug and provides ideas for subsequent research directions.
